Abstract
Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.
| Original language | English |
|---|---|
| Pages (from-to) | 488-494 |
| Number of pages | 7 |
| Journal | Journal of Chemotherapy |
| Volume | 15 |
| Issue number | 5 |
| Publication status | Published - Oct 2003 |
Fingerprint
Keywords
- Breast cancer
- Doxorubicin
- Gemcitabine
- Paclitaxel
- Phase I trial
ASJC Scopus subject areas
- Pharmacology (medical)
- Microbiology (medical)
Cite this
Doxorubicin, Paclitaxel and Gemcitabine : A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer. / Ibrahim, T.; Fabbri, M.; Frassineti, G. L.; Zoli, W.; Monti, M.; Ricotti, L.; Amadori, D.
In: Journal of Chemotherapy, Vol. 15, No. 5, 10.2003, p. 488-494.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Doxorubicin, Paclitaxel and Gemcitabine
T2 - A Phase I Study of a New Sequential Treatment in Stage III B - IV Breast Cancer
AU - Ibrahim, T.
AU - Fabbri, M.
AU - Frassineti, G. L.
AU - Zoli, W.
AU - Monti, M.
AU - Ricotti, L.
AU - Amadori, D.
PY - 2003/10
Y1 - 2003/10
N2 - Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.
AB - Based on the synergistic interactions of the sequence doxorubicin- paclitaxel-gemcitabine obtained in our preclinical study, a Phase I trial was conducted to evaluate the feasibility of this new sequence in breast cancer. Patients with stage IIIB-IV breast cancer received doxorubicin on day 1, paclitaxel on day 2 and gemcitabine on day 6 and 13 (steps IIa, III and V) in cohorts of 3 patients. From March 1999 to December 2000, 9 patients were treated. The most important toxicity was hematological. The maximum tolerated dose was reached at the second level because dose-limiting toxicity occurred in 3 patients. Non hematological toxicities were alopecia, diarrhea, asthenia, nausea, mucositis, paresthesia and myalgia. A Phase II trial is ongoing to further investigate the activity of this new sequential treatment with doxorubicin (50 mg/m 2 day 1), paclitaxel (160 mg/m 2 day 2) and gemcitabine (800 mg/m 2 day 6) in advanced breast cancer.
KW - Breast cancer
KW - Doxorubicin
KW - Gemcitabine
KW - Paclitaxel
KW - Phase I trial
UR - http://www.scopus.com/inward/record.url?scp=0142154947&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0142154947&partnerID=8YFLogxK
M3 - Article
C2 - 14598942
AN - SCOPUS:0142154947
VL - 15
SP - 488
EP - 494
JO - Journal of Chemotherapy
JF - Journal of Chemotherapy
SN - 1120-009X
IS - 5
ER -